Clinical Collaboration & Licensing Asia-Pacific · 14d ago

CStone and Kimia Therapeutics Partner to Advance Potential First-in-Class DNA Damage Response Therapy for Solid Tumors in China and Australia

CStone Pharmaceuticals and Kimia Therapeutics launch a clinical collaboration to advance a potential first-in-class DNA damage response (DDR) asset for sol

RD

Research Desk

· 3 min read

CStone and Kimia Therapeutics Partner to Advance Potential First-in-Class DNA Damage Response Therapy for Solid Tumors in China and Australia

Suzhou, China–based CStone Pharmaceuticals (HKEX: 2616) announced on November 4, 2026, that it has entered into a clinical collaboration agreement with Kimia Therapeutics, Inc., a Berkeley, California–based biopharmaceutical company developing innovative therapeutics for oncology and immunology.

Collaboration Announced to Advance Novel DDR-Targeting Asset

The agreement is aimed at advancing the clinical development of a potential first-in-class asset targeting the DNA damage response (DDR) pathway, which is described as critical for solid tumor cell survival. Under the collaboration, CStone will lead the clinical development of the asset in mainland China and Australia.

The companies stated that the collaboration reflects international recognition of CStone's clinical development and regulatory expertise and supports the company's strategy of disciplined external innovation and global expansion.

It also creates a pathway for CStone to participate in the global commercial value of a first-in-class asset through milestone payments and royalties.

Division of Responsibilities Under a Co-Development Model

Under the terms of the agreement, CStone will lead the Phase I clinical development of the asset in mainland China and Australia, applying what the company describes as its full-spectrum oncology clinical development and regulatory capabilities.

Kimia will contribute the clinical supply of the asset, along with scientific guidance, product-related regulatory oversight, and other agreed-upon development support. The arrangement is characterized by the companies as a co-development model built on each party's complementary strengths.

Kimia will reimburse CStone for the applicable clinical development costs. CStone is eligible to receive milestone payments plus royalties on global net sales of the asset during the applicable royalty term, in accordance with the agreement.

Phase I Study Design and Target Populations

The planned Phase I study includes dose-escalation and expansion components to evaluate the asset in biomarker-selected patient populations as an initial proof-of-concept. The study is designed to define safety, pharmacokinetics, pharmacodynamics, and early activity of the asset.

Kimia's AI-Driven Discovery Platform and Investment Backing

Kimia Therapeutics is advancing small-molecule medicines using its integrated ATLAS platform, which the company describes as a transformative approach to AI-driven drug discovery. According to the announcement, the proprietary ATLAS platform combines nanogram-scale parallel synthesis, direct-to-biology screening, and machine learning.

Kimia is a portfolio company of The Column Group (TCG), a life sciences investment firm focused on building and investing in biotechnology companies from early-stage scientific innovation through clinical development and strategic transactions.

Kimia CEO Stig Hansen said the company was delighted to work with CStone to advance the clinical development of the potential first-in-class asset, which was discovered by Kimia leveraging AI and medicinal chemistry integration.

He noted that CStone's expertise in oncology clinical development will be valuable as Kimia evaluates its lead asset in Phase I proof-of-concept studies in biomarker-selected patient populations.

CStone's Development Track Record and Strategic Rationale

The collaboration pairs CStone's oncology clinical development and regulatory expertise across multiple markets with Kimia's AI-enabled drug discovery approach. CStone's track record includes four approved innovative drugs and 21 new drug application approvals across nine indications.

Dr. Jason Yang, Chief Executive Officer, President of R&D, and Executive Director of CStone, said the company is pleased to collaborate with Kimia to advance the innovative, first-in-class oncology asset.

He described the collaboration as establishing a scalable framework with the potential to support additional programs with Kimia and other TCG portfolio companies, connecting promising innovation with a clear path to efficient and robust clinical development.

He added that the deal structure aligns the parties' shared commitment to the asset's development and long-term success while providing CStone with the opportunity to participate in the value it creates globally. Yang characterized the repeatable model as an important avenue to broaden CStone's participation in global innovation and create long-term value for its shareholders.

Framework for Future Extensions

Beyond the current asset, the collaboration establishes a scalable framework that may be extended to other promising assets over time.

According to the announcement, this creates a repeatable model for CStone to contribute its clinical development expertise to advancing innovative therapies, generate value through milestone payments and royalties, and expand its international development footprint.

Tracked in the database

Clinical Collaboration & Licensing · Asia-Pacific

Category

Clinical Collaboration & Licensing

Region

Asia-Pacific

Industry

Chemical

Published

4 November 2026

Length

3 min read

Tagged

Clinical CollaborationOncology Drug DevelopmentDNA Damage Response (DDR)First-in-Class Asset

Live from the tracker

The projects behind these stories

Capacity, capex, stage, contractors and verified contacts for every project we track, updated daily.

LLY - Lebanon Medicine Foundry · Indiana, United States · Not disclosed · On-going / Under Construction LLY - Project Savannah Biomanufacturing Facility · Texas, United States · Not disclosed · Planning LLY - Huntsville Medicines Manufacturing Plant · Alabama, United States · Not disclosed · Planning NOVO-B - Clayton Aseptic and Finished Product Manufacturing Plant · North Carolina, United States · Not disclosed · On-going / Under Construction LLY - Pleasant Prairie Pharmaceutical Manufacturing Facility Expansion · Wisconsin, United States · Not disclosed · Planning EDCL - Gopalganj Vaccine Manufacturing Plant · Dhaka Division, Bangladesh · Not disclosed · Planning FF - Holly Springs Cell Culture Biomanufacturing Plant · North Carolina, United States · Not disclosed · On-going / Under Construction LLY - Leiden Bio Science Park Pharmaceutical Manufacturing Plant · Netherlands · Not disclosed · Planning LLY - Alzey Pharmaceuticals Production Plant · Rhineland-Palatinate, Germany · Not disclosed · On-going / Under Construction BAYN - New Albany Pharmaceutical Manufacturing Plant · Ohio, United States · Not disclosed · Planning LLY - Lebanon Medicine Foundry · Indiana, United States · Not disclosed · On-going / Under Construction LLY - Project Savannah Biomanufacturing Facility · Texas, United States · Not disclosed · Planning LLY - Huntsville Medicines Manufacturing Plant · Alabama, United States · Not disclosed · Planning NOVO-B - Clayton Aseptic and Finished Product Manufacturing Plant · North Carolina, United States · Not disclosed · On-going / Under Construction LLY - Pleasant Prairie Pharmaceutical Manufacturing Facility Expansion · Wisconsin, United States · Not disclosed · Planning EDCL - Gopalganj Vaccine Manufacturing Plant · Dhaka Division, Bangladesh · Not disclosed · Planning FF - Holly Springs Cell Culture Biomanufacturing Plant · North Carolina, United States · Not disclosed · On-going / Under Construction LLY - Leiden Bio Science Park Pharmaceutical Manufacturing Plant · Netherlands · Not disclosed · Planning LLY - Alzey Pharmaceuticals Production Plant · Rhineland-Palatinate, Germany · Not disclosed · On-going / Under Construction BAYN - New Albany Pharmaceutical Manufacturing Plant · Ohio, United States · Not disclosed · Planning